论文部分内容阅读
目的:评价低剂量替吉奥联合奥沙利铂治疗高龄晚期贲门癌的近期疗效和安全性。方法:60例年龄75岁以上晚期GCA按区组随机法分为低剂量组32例和对照组28例,替吉奥低剂量组50 mg/m~2,对照组80 mg/m~2,均bid口服,d1～d14,同时联合L-OHP 65 mg/m~2静滴2 h,d1,d8,21 d为1个周期,至少完成4个周期。结果:低剂量组与对照组有效率(RR)分别为59.4%、59.3%;疾病控制率(DCR)分别为93.8%、88.9%,差异均无统计学意义(P>0.05);不良反应发生率低剂量组、对照组中性粒细胞减少分别为46.9%、75.0%;贫血分别为53.1%、78.6%;血小板减少分别为43.8%、71.4%,差异均具有统计学意义(P<0.05)。结论:替吉奥50mg/m~2联合奥沙利铂治疗高龄晚期贲门癌,与80mg/m~2比较疗效相近,不良反应发生率降低,患者耐受性和治疗依从性更好,推荐进一步研究应用。
OBJECTIVE: To evaluate the short-term efficacy and safety of low-dose tegaserod plus oxaliplatin in the treatment of advanced cardia cancer of the elderly. Methods: Sixty elderly GCA patients over the age of 75 were divided into two groups according to randomization: 32 cases in the low dose group and 28 cases in the control group, 50 mg / m ~ 2 for the low dose group and 80 mg / All patients were dosed with oral d1 ~ d14, and intravenous infusion of L-OHP 65 mg / m ~ 2 for 2 h. D 1, d 8 and 21 d were performed in one cycle, at least 4 cycles were completed. Results: The RR of low dose group and control group were 59.4% and 59.3%, respectively. The disease control rates (DCR) were 93.8% and 88.9% respectively, with no significant difference (P> 0.05). Adverse reactions The rates of neutropenia were 46.9% and 75.0% in the low dose group and the control group respectively. The anemia was 53.1% and 78.6% respectively. The thrombocytopenia was 43.8% and 71.4% respectively, with statistical significance (P <0.05) . Conclusion: The effect of treatment of 50mg / m ~ 2 and oxaliplatin in the treatment of advanced cardia cancer of the elderly is similar to that of 80mg / m ~ 2, the incidence of adverse reactions is reduced, and the patient tolerance and treatment compliance are better. Research and application.